Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco C, Sahuquillo-Torralba A, Mateu-Puchades A, Pitarch-Bort G, Marí-Ruiz JI, Mataix-Díaz J, Montesinos-Villaescusa E, Miralles-Botella J, García-Fernández L, Martorell-Calatayud A, Belinchón-Romero I, Sánchez-Carazo JL, Pérez-Ferriols A. Ortiz-Salvador JM, et al. Among authors: mateu puchades a. J Am Acad Dermatol. 2019 Aug;81(2):427-432. doi: 10.1016/j.jaad.2019.02.062. Epub 2019 Mar 11. J Am Acad Dermatol. 2019. PMID: 30872150 Free article.
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Nieto-Benito LM, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferrán Farrés M, Alsina M, Fernández-Freire LR, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Ruiz-Genao DP, Riera-Monroig J, Descalzo Gallego MÁ, García-Doval I; BIOBADADERM Study Group. Baniandrés-Rodríguez O, et al. J Am Acad Dermatol. 2021 Feb;84(2):513-517. doi: 10.1016/j.jaad.2020.10.046. Epub 2020 Oct 26. J Am Acad Dermatol. 2021. PMID: 33122022 Free PMC article. No abstract available.
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Berenguer-Ruiz S, et al. Among authors: mateu puchades a. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2517-2525. doi: 10.1111/jdv.19468. Epub 2023 Sep 1. J Eur Acad Dermatol Venereol. 2023. PMID: 37625815
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R, Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferran-Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Suarez-Perez JA, González-Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, Del Alcázar-Viladomiu E, García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-Velasco M, Vilarrasa E, Velasco-Pastor M, De la Cueva P, Carrascosa JM, Magdaleno-Tapial J. Martorell A, et al. Among authors: mateu puchades a. Actas Dermosifiliogr. 2024 Mar 6:S0001-7310(24)00187-X. doi: 10.1016/j.ad.2024.02.030. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 38452889 English, Spanish.
52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
Melgosa Ramos FJ, Mateu Puchades A, Matáix-Díaz J, Schneller-Pavelescu L, Belinchón-Romero I, Santos Alarcón S. Melgosa Ramos FJ, et al. Among authors: mateu puchades a. Actas Dermosifiliogr. 2024 Jul-Aug;115(7):722-726. doi: 10.1016/j.ad.2023.08.019. Epub 2024 Mar 29. Actas Dermosifiliogr. 2024. PMID: 38556201 Free article. English, Spanish.
[No title available]
[No authors listed] [No authors listed] PMID: 38777224
Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL. Mateu-Puchades A, et al. Dermatol Ther. 2018 Jul;31(4):e12607. doi: 10.1111/dth.12607. Epub 2018 Apr 16. Dermatol Ther. 2018. PMID: 29663615 No abstract available.
Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis.
García-Martínez P, Collado-Díaz V, Mateu-Puchades A, Villarroel-Vicente C, Rovira-Llopis S, Blas-García A, Álvarez Á, Esplugues JV, Andújar I. García-Martínez P, et al. Among authors: mateu puchades a. J Invest Dermatol. 2020 Nov;140(11):2294-2298.e6. doi: 10.1016/j.jid.2020.02.039. Epub 2020 Apr 18. J Invest Dermatol. 2020. PMID: 32311396 Free article. No abstract available.
91 results